Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1852 1
1857 1
1875 1
1881 3
1882 2
1883 1
1884 3
1885 2
1887 2
1888 2
1889 1
1890 1
1892 2
1899 1
1901 2
1903 3
1904 1
1906 1
1908 1
1909 5
1910 1
1912 2
1918 1
1919 2
1922 1
1924 1
1926 1
1929 1
1931 1
1934 1
1935 2
1940 1
1941 1
1942 1
1943 1
1945 1
1946 10
1947 16
1948 12
1949 11
1950 14
1951 23
1952 25
1953 20
1954 21
1955 15
1956 28
1957 25
1958 28
1959 21
1960 14
1961 21
1962 23
1963 28
1964 33
1965 56
1966 47
1967 41
1968 68
1969 65
1970 62
1971 52
1972 62
1973 61
1974 81
1975 60
1976 84
1977 79
1978 81
1979 78
1980 77
1981 82
1982 99
1983 99
1984 114
1985 115
1986 128
1987 105
1988 135
1989 148
1990 156
1991 144
1992 143
1993 129
1994 154
1995 171
1996 179
1997 161
1998 153
1999 178
2000 211
2001 261
2002 255
2003 282
2004 404
2005 469
2006 529
2007 628
2008 723
2009 860
2010 954
2011 1401
2012 1558
2013 1887
2014 2309
2015 2633
2016 2889
2017 3107
2018 3465
2019 4089
2020 5104
2021 5904
2022 6289
2023 6650
2024 2385

Text availability

Article attribute

Article type

Publication date

Search Results

52,407 results

Results by year

Filters applied: . Clear all
Page 1
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).
Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Xu X, et al. Signal Transduct Target Ther. 2022 Aug 13;7(1):287. doi: 10.1038/s41392-022-01119-3. Signal Transduct Target Ther. 2022. PMID: 35963848 Free PMC article. Review.
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading cause of liver disease worldwide. ...Importantly, growing evidence elucidates that the disruption of the gut-liver axis and microbe-derived metabolites …
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading cause of liver disease …
Current treatment paradigms and emerging therapies for NAFLD/NASH.
Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Raza S, et al. Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892. Front Biosci (Landmark Ed). 2021. PMID: 33049668 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, may culminate into cirrhosis and …
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syn …
Triggering and resolution of inflammation in NASH.
Schuster S, Cabrera D, Arrese M, Feldstein AE. Schuster S, et al. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364. doi: 10.1038/s41575-018-0009-6. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29740166 Review.
Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis. A central issue in …
Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty liver disease (NAFL …
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Younossi Z, et al. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20. Nat Rev Gastroenterol Hepatol. 2018. PMID: 28930295 Free article. Review.
NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. ...The large number of pati …
NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stag …
Challenges and opportunities in NASH drug development.
Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Harrison SA, et al. Nat Med. 2023 Mar;29(3):562-573. doi: 10.1038/s41591-023-02242-6. Epub 2023 Mar 9. Nat Med. 2023. PMID: 36894650 Review.
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical need, as no licensed drugs have been approved thus far. ...Over the past decades, se …
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), represen …
Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y, Yoneda M. Sumida Y, et al. J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16. J Gastroenterol. 2018. PMID: 29247356 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. ...The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortal …
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no a …
Preparing for the NASH Epidemic: A Call to Action.
Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Kanwal F, et al. Gastroenterology. 2021 Sep;161(3):1030-1042.e8. doi: 10.1053/j.gastro.2021.04.074. Epub 2021 Jul 26. Gastroenterology. 2021. PMID: 34416976 Free article.
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Furt …
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a ri …
Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid.
Wei W, Wong CC, Jia Z, Liu W, Liu C, Ji F, Pan Y, Wang F, Wang G, Zhao L, Chu ESH, Zhang X, Sung JJY, Yu J. Wei W, et al. Nat Microbiol. 2023 Aug;8(8):1534-1548. doi: 10.1038/s41564-023-01418-7. Epub 2023 Jun 29. Nat Microbiol. 2023. PMID: 37386075 Free PMC article.
Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease, and is characterized by liver inflammation and fat accumulation. ...Mechanistically, inulin, P. distasonis or pentadecanoic …
Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver dis …
The Role of Cholesterol in the Pathogenesis of NASH.
Ioannou GN. Ioannou GN. Trends Endocrinol Metab. 2016 Feb;27(2):84-95. doi: 10.1016/j.tem.2015.11.008. Epub 2015 Dec 17. Trends Endocrinol Metab. 2016. PMID: 26703097 Review.
Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellul …
Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty …
Determinants of fibrosis progression and regression in NASH.
Schuppan D, Surabattula R, Wang XY. Schuppan D, et al. J Hepatol. 2018 Feb;68(2):238-250. doi: 10.1016/j.jhep.2017.11.012. Epub 2017 Nov 14. J Hepatol. 2018. PMID: 29154966 Review.
Cirrhosis has become the major liver-related clinical endpoint in non-alcoholic steatohepatitis (NASH). ...The advent of novel, highly sensitive and specific serum biomarkers and imaging methods to assess the dynamics of liver fibrosis in NAS …
Cirrhosis has become the major liver-related clinical endpoint in non-alcoholic steatohepatitis (NASH). ...The a …
52,407 results
You have reached the last available page of results. Please see the User Guide for more information.